Avraham Pharmaceuticals (“Avraham”) is a privately held, emerging pharmaceutical company developing novel products for treatment and/or prevention of neurodegenerative disorders. Founded in 2010, Avraham has raised $9 million to conduct a European Phase II proof-of-concept efficacy trial in patients with Alzheimer's disease, supporting the development of its lead product candidate, ladostigil.
Funding Rounds (4) - $4.5MUpdate
Integra LifeSciences Holdings Corporation (Integra) is an integrated medical device company.
Technion Research & Development Foundation Ltd. (TRDF) offers a unique gateway to the...
Powering Tomorrow's Biopharma Companies
Venture capital Firm
42 Hayarkon st.
Northern Industrial Zone